<div id="readability-page-1"><p>Truist Financial began coverage on shares of <span>Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report)</span> in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a &#34;buy&#34; rating and a $56.00 price target on the stock. Truist Financial's target price indicates a potential upside of 62.70% from the company's current price.</p><div><p><span></span><span>Get <strong>Dianthus Therapeutics</strong> alerts:</span></p></div><p>Other equities analysts have also issued research reports about the company. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Guggenheim upped their price objective on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 9th. Stifel Nicolaus upped their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, September 12th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an &#34;outperform&#34; rating for the company. Finally, HC Wainwright  reaffirmed a &#34;buy&#34; rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, September 8th. Ten analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $60.88.</p><p><b>Check Out Our Latest Research Report on Dianthus Therapeutics</b></p><h2>Dianthus Therapeutics Stock Performance</h2><p>NASDAQ:DNTH opened at $34.42 on Tuesday. The stock has a 50-day simple moving average of $29.81 and a two-hundred day simple moving average of $22.83. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $40.16. The firm has a market capitalization of $1.11 billion, a PE ratio of -10.59 and a beta of 1.58. </p><p>Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%.  Equities analysts forecast that  Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year. </p><h2>Insider Activity</h2><p>In other news, CFO Ryan Savitz sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 16.56% of the stock is owned by insiders. </p><h2>Institutional Investors Weigh In On Dianthus Therapeutics</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC raised its holdings in shares of  Dianthus Therapeutics by 3.4% in the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock worth $332,000 after buying an additional 602 shares during the period.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of  Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after buying an additional 618 shares during the period.  Bank of New York Mellon Corp raised its holdings in shares of  Dianthus Therapeutics by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after buying an additional 748 shares during the period.  Charles Schwab Investment Management Inc. raised its holdings in shares of  Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock worth $3,049,000 after buying an additional 1,081 shares during the period.  Finally, Raymond James Financial Inc. purchased a new stake in shares of  Dianthus Therapeutics in the second quarter worth approximately $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About Dianthus Therapeutics</h2> (Get Free Report)<p>Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.</p><h2>See Also</h2><ul><li>Five stocks we like better than Dianthus Therapeutics</li><li>Business Services Stocks Investing</li><li>Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?</li><li>Investing in Commodities: What Are They? How to Invest in Them</li><li>Why Congress Is Buying Intuitive Surgical Ahead of Earnings</li><li>3 Grocery Stocks That Are Proving They Are Still Essential </li><li>FICO’s Big Dip Could Be the Best Buying Chance of the Year</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dianthus Therapeutics Right Now?</h2><p>Before you consider Dianthus Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.</p><p>While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DNTH

<p>Truist Financial has initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH), assigning a "buy" rating and a price target of $56.00, indicating a potential upside of 62.70%. Other analysts have varied opinions, with Weiss Ratings giving a "sell" rating, while Guggenheim and Stifel Nicolaus have set higher price targets of $100.00 and $65.00, respectively. The stock currently trades at $34.42, with an average rating of "Moderate Buy" and a target price of $60.88. Dianthus is a clinical-stage biotech firm focused on treatments for autoimmune diseases.</p>

Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Analysts at Truist Financial